Thursday, November 14, 2019 10:05:47 AM
With a rating of Buy, Roth Capital initiated coverage on Arvinas Inc (NASDAQ:ARVN). The price target is set at $35.00 for Arvinas. In the third quarter, Arvinas showed an EPS of $0.21, compared to ($62.38) from the year-ago quarter. The current market cap for Arvinas is at $696.1 million. The stock has a 52-week-high of $28.96 and a 52-week-low of $10.19. Arvinas's stock last closed at $28.38 per share.
I might post a chart in about a week, well after everything plays out!
There's a sucker born every minute!
-Some Circus Dude
Recent ARVN News
- Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer • GlobeNewswire Inc. • 04/11/2024 11:00:49 AM
- Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer • GlobeNewswire Inc. • 03/18/2024 08:40:46 PM
- Arvinas to Participate in Upcoming Investor Conferences • GlobeNewswire Inc. • 03/04/2024 12:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:35:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:34:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:33:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 11:33:04 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2024 09:46:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 12:02:59 PM
- Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/27/2024 12:00:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2024 09:06:49 PM
- Arvinas Announces Chief Financial Officer Transition • GlobeNewswire Inc. • 02/20/2024 09:05:04 PM
- Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease • GlobeNewswire Inc. • 02/20/2024 12:00:44 PM
- Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer • GlobeNewswire Inc. • 02/14/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:14:06 AM
- Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer • GlobeNewswire Inc. • 02/06/2024 11:45:00 AM
- Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference • GlobeNewswire Inc. • 02/01/2024 09:30:20 PM
- Arvinas Appoints Jared Freedberg as General Counsel • GlobeNewswire Inc. • 01/16/2024 10:01:06 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/16/2024 09:03:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 09:39:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:45:42 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 12/08/2023 02:16:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/06/2023 12:01:32 PM
- Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program • GlobeNewswire Inc. • 12/06/2023 03:52:59 AM
- Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program • GlobeNewswire Inc. • 12/05/2023 06:33:42 PM
Coinllectibles' Subsidiary, Grand Town Development Limited, Acquires Rare Song Dynasty Ceramics Worth Over USD28million • COSG • Apr 18, 2024 8:03 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • GCTK • Apr 17, 2024 8:00 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM